Heterogeneity of Baló's concentric sclerosis: a study of eight cases with different therapeutic concepts.
Dimitrios TzanetakosA G VakrakouJ S TzartosG VelonakisM E EvangelopoulosM AnagnostouliG KoutsisE DardiotisE KaravasilisP ToulasL StefanisC KilidireasPublished in: BMC neurology (2020)
Our study introduces a new insight regarding the categorization of BCS into three subgroups depending on radiological features at onset and during the course of the disease, in combination with the response to different immunotherapies. Immunosuppressive agents such as cyclophosphamide are usually effective in BCS. However, therapeutic alternatives like anti-CD20 monoclonal antibodies or more classical disease-modifying MS therapies can be considered when BCS has also mixed lesions similar to MS. Future studies with a larger sample size are necessary to further establish these findings, thus leading to better treatment algorithms and improved clinical outcomes.